Plasmodium Falciparum Clinical Trial
Official title:
Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam
Resistance of Plasmodium falciparum toward Artemisinins, the most important drug for the successful treatment of malaria, has been confirmed in Cambodia. There are few reports from neighbouring countries about delayed parasite rates. The investigators therefore aim to assess parasite clearance in malaria patients in central Vietnam when treated according to national standard guidelines.
General objective To evaluate the efficacy of DHA-PPQ in patients with uncomplicated
falciparum malaria in a rural area of Central Vietnam, and to assess the in vitro
susceptibility of P.falciparum isolates to DHA and PPQ.
Specific objectives
1. To measure the parasite clearance time in falciparum malaria patients treated with
DHA-PPQ.
2. To determine the efficacy of DHA-PPQ at day 42 post-treatment.
3. To assess the in vitro susceptibility of P.falciparum isolates towards DHA and PPQ in
Quang Nam Province.
4. To compare genetic profiles of P.falciparum isolates with delayed and those with normal
clearance times in order to identify potential markers of resistance;
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01935882 -
Low Dose Primaquine for Clearance of Gametocytes
|
Phase 2/Phase 3 | |
| Completed |
NCT01728701 -
Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis
|
Phase 1 | |
| Completed |
NCT00914225 -
Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya
|
N/A | |
| Completed |
NCT02895568 -
Prevalence Survey of Plasmodium Falciparum Antimalarial Drug Resistance Markers
|
||
| Completed |
NCT02259426 -
Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission
|
Phase 3 | |
| Completed |
NCT01465048 -
Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe
|
N/A | |
| Completed |
NCT00392015 -
NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1
|
Phase 1/Phase 2 | |
| Completed |
NCT04661579 -
RTS,S/AS01E Hypo-immuno-responsiveness Study
|
Phase 2 | |
| Recruiting |
NCT05400746 -
A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK
|
Early Phase 1 | |
| Completed |
NCT03138096 -
Safety and Protective Efficacy of Pb(PfCS@UIS4)
|
Phase 1/Phase 2 | |
| Completed |
NCT03452475 -
Comparison of Arterolane-piperaquine Versus Arterolane-piperaquine+Mefloquine Versus Artemether-lumefantrine in Kenyan Children
|
Phase 3 | |
| Completed |
NCT00295581 -
PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria
|
Phase 1 | |
| Withdrawn |
NCT04203186 -
A Clinical Trial to Evaluate Plasmodium Falciparum 7G8 and NF54 Challenge Strains (PfSPZ) in a Head-to-head Comparative Study - (ECG-CHMI)
|
N/A | |
| Completed |
NCT02418962 -
Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults
|
Phase 1 | |
| Completed |
NCT01160562 -
Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity
|
||
| Terminated |
NCT04445103 -
The Malaria Heart Disease Study
|
||
| Completed |
NCT03132402 -
ELISA Validation of Hypersensitive Rapid Diagnostic Test Results for Detection of P. Falciparum
|
||
| Completed |
NCT03172221 -
Clinical Performance of the HRP2 HS-RDT for Malaria Diagnosis in Pregnant Women
|
||
| Not yet recruiting |
NCT03219281 -
Prevalence Survey of Antimalarial Drug Resistance Markers at Sites in India
|
N/A | |
| Completed |
NCT02090036 -
Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
|
Phase 4 |